Cervical cancer research addresses HPV vaccination and screening, chemoradiation sequencing, and immunotherapy in recurrent or metastatic disease.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
An exploratory analysis of the phase 3 KEYNOTE-826 trial reports that adding pembrolizumab to platinum-based chemotherapy (with or without bevacizumab) continues to show longer overall and progression-free survival than chemotherapy alone in persistent, recurrent, or metastatic cervical cancer, at a median follow-up of roughly five years (59.1 months).
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.